Program

Click here to download the SSM9 preliminary program

SSM9 Program

SUNDAY, July 2nd, 2017

Venue: Room Fèlix Serratosa, Barcelona Science Park (PCB)

15:00 – 16:00      Registration

16:00 – 16:30      OFFICIAL OPENING – 9th Summer School on Medicines (SSM9)

Jordi Fàbrega, Director of Business Development Area at Biocat, Chairman.

Ignasi Belda, General Director at Barcelona Science Park

Pierre Cordelier, Professor and Researcher at INSERM U1037, Toulouse Oncopole & Université Paul Sabatier III, Toulouse, Chairman

Denis deBlois, Pharmacy Faculty Director of Université de Montréal, Québec, Chairman

Rémy Poupot, Professor and researcher at INSERM, Université Paul Sabatier, Toulouse

Jordi Quintana, SSM9 Scientific Committee, Chairman

16:30 – 18:30      Keynote Sessions

Keynote Session 1 (KNS1):

Developing a new model of partnership between academia and the pharmaceutical industry; a focus on G protein-coupled receptor as an evolving drug target family

Michel Bouvier, Department of Biochemistry, Institute for Research in Immunology and Cancer (IRIC), Université de Montréal, Québec

Keynote Session 2 (KNS2):

Swimming with the sharks (Oryzon’s quest for drugs to treat cancer and neurodegeneration)

Jordi Salas, Senior Project Leader at Oryzon

 18:30 – 20:30     Welcome Reception at Clúster Terrace / Barcelona Science Park (PCB)


MONDAY, July 3rd, 2017

Venue: Room Fèlix Serratosa, Barcelona Science Park (PCB)

SESSION I: DRUG R&D, AN OVERVIEW FROM IDEA TO MARKET

Chairperson: Denis deBlois, Jordi Quintana

09:00 – 10:30      (S1) Drug Discovery Overview

Denis deBlois, Pharmacy Faculty Director of Université de Montréal, Québec

10:30 – 11:00        Health Break

11:00 – 12:30      (S2) Drug Development Overview

Manuel Merlos, Director of Pharmacology at Esteve R+D

12:30 – 13:30      (S3) Beyont the Pill 1 (Precision Medicine / Genomics)

Ivo Gut, Director of Centre for Genomic Regulation (CRG)

13:30 – 14:30      Lunch (PCB Restaurant)

14:30 – 15:00      Visit to PCB facilities

SESSION II: DRUG DISCOVERY

Chairperson: Jordi Quintana

15:00 – 15:45      (S4) Chemical Biology / Drug Design / Systems Pharmacology

Jordi Mestres, Head of the Systems Pharmacology Group at Hospital del Mar

Medical Research Institute (IMIM), University Pompeu Fabra

15:45 – 16:30      (S5) Medicinal Chemistry 

Carme Almansa, Chemistry Director at Esteve

16:30 – 17:00      Health Break

17:00 – 17:45      (S6) New classes of biological drugs: Cell and gene therapy products

Pierre Cordelier, Professor and Researcher at INSERM U1037, Toulouse Oncopole & Université Paul Sabatier, Toulouse

17:45 – 18:30      Plenary discussion with speakers


TUESDAY, July 4th, 2017

Venue: Room Fèlix Serratosa, Barcelona Science Park (PCB)

SESSION III: FROM DRUG DISCOVERY TO EARLY CLINICAL DEVELOPMENT (I)

Chairperson: Denis deBlois, Pierre Cordelier

09:00 – 9:45       (S7) ADME (Pharmacokinetics / Pharmacodynamics)

Ismael Zamora, Associate Professor at Universitat Pompeu Fabra, CEO of Lead Molecular Design, S.L

9:45 – 10:30      (S8) Drug Delivery & Pharmaceutical Development

PierAndrea Esposito, Associate Director of SiTec PharmaBio

10:30 – 11:00      Health Break

11:00 – 11:45      (S9) Drug Discovery of dendrimers: From idea to optimization

Cédric-Olivier Turrin, Laboratoire de Chimie de Coordination, CNRS, Toulouse

Rémy Poupot, Professor at University of Toulouse, INSERM

11:45 – 12:30     (S10) Drug development of dendrimers: Animal models, preclinical development, computation

Cédric-Olivier Turrin, Laboratoire de Chimie de Coordination, CNRS, Toulouse

Rémy Poupot, Professor at University of Toulouse, INSERM

12:30 – 13:30       (S11) Beyond the Pill 2 (Multifunctional nanovesicles for drug delivery applications)

Jaume Veciana, Head Department at ICMAB

13:30 – 14:30       Lunch (PCB Restaurant)

SESSION IV: CASE STUDY IN DRUG DISCOVERY AND DEVELOPMENT 

Chairperson: Denis deBlois, Rémy Poupot, Pierre Cordelier

14:30 – 15:00      Case presentation and outline of challenges

15:00 – 16:00      Group session 

16:00 – 16:30      Health break

16:30 – 18:00      Each team reports / General discussion


WEDNESDAY, July 5th, 2017

Venue: Room Fèlix Serratosa, Barcelona Science Park (PCB)

SESSION V: FROM DRUG DISCOVERY TO EARLY CLINICAL DEVELOPMENT (II)

Chairperson: Jordi Quintana

09:00 – 09:45     (S12) Public-private partnerships. A view from the pharmaceutical industry

Andrés Fernández, Director at Ferrer Advanced Biotherapeutics

09:45 – 10:30      (S13) Toxicology / Preclinical Safety

Antonio Guzmán, Head of the Toxicology Department at Esteve

10:30 – 11:00      Health Break

11:00 – 11:45      (S14) Chemical Process Development and Manufacturing of an API

Ramón Berenguer, Process R&D Director at Esteve Química 

11:45 – 12:30      (S15) Learning and confirming trials

Denis deBlois, Pharmacy Faculty Director of Université de Montréal, Québec

12:30 – 13:30      SSM9 Students Presentations 

13:30 – 14:30      Lunch (PCB Restaurant)

14:30 – 15:30      Visit to CNAG-CRG (National Center for Genomic Analysis) (PCB)

15:30 – 17:00      Visit to Esteve Preclinical R+D laboratories (PCB)


THURSDAY, July 6th, 2017

Venue: Room Fèlix Serratosa, Barcelona Science Park (PCB)

SESSION VI: CLINICAL DEVELOPMENT / REGULATORY

Chairperson: Denis deBlois

9.00 – 9:45        (S16) Clinical Phases 

Anne Leselbaum, Medical Consultant at Clinical Drug Development

9:45 – 10:30       (S17) Benefit / Risk Assessment / Pharmacovigilance

Alice Dragomir, Assistant Professor at Research Institute of McGill University Health Center

10:30 – 11:00      Health break

11:00 – 11:45      (S18) Pharmaco-economics in drug development

Oriol Solà-Morales, CEO and Founder of HITT – Health Innovation Technology Transfer, SAGESSA, Universitat Internacional de Catalunya (UIC)

11:45 – 12:30      (S19) Regulatory Development Strategy

Xavier Luria, Senior Consultant at Drug Development and Regulation

12:30 – 13:30       (S20) Beyond the Pill 3 (Medical devices: from idea to first sales – an entrepreneur’s point of view)

Markus Wilhelms,CEO & Co-Founder at usMIMA & MOWOOT

13:30 – 14:30       Lunch ( PCB Restaurant)

14:30 – 15:15      (S21) New models in Tech Transfer: Spherium Biomed

Pedro Grima, Senior Project Manager at Spherium Biomed

15:15 – 16:00      (S22) Ideas-Team-Commitment, three pillars of entrepreneurial success

Albert Palomer, CEO at ABAC Therapeutics

16:00 – 16:45       (S23) The role and value of pharmaceutical marketing.

Laurence Mickalonis, President and Senior Partner at Life Science Praxis

16:45 – 17:45     SSM9 Students Presentations 


FRIDAY, July 7th, 2017

Venue: Room Fèlix Serratosa, Barcelona Science Park (PCB)

SESSION VII: PHARMACO ECONOMICS & INTELLECTUAL PROPERTY

Chairperson: Jordi Fàbrega

09:00 – 09:45     (S24) IP Protection in the Pharmaceutical Industry

Enric Carbonell, Partner at ABG Patents

9:45 – 10:30       (S25) Market access

Nerea Alonso, Partner at AEC Consultants

10:30 – 11:00     Health Break

SESSION VIII: PUBLIC-PRIVATE / CONTRACT RESEARCH & BUSINESS DEVELOPMENT

Chairperson: Jordi Fàbrega

11:00 – 11:45      (S26) Contract Research & Contract Business Development 

Daniel González, Vice-President Business Development at Trifermed

11:45 – 12.30      (S27) Patients empowerment. Their role in the Drug Discovery & Development

Marta Príncep, CEO of Fundació GAEM

12:30 – 13:30      (S28) Beyond the Pill 4 (New technologies: Photopharmacology)

Amadeu Llebaria, research scientist at CSIC

13:30 – 15:00      Lunch (PCB Restaurant)

SESSION IX: CLOSING SESSION

Chairperson: Jordi Fàbrega

15:00 – 15:45      Closing Keynote Sesion: From idea to clinical trials

Raúl Insa, CEO of SOM Biotech

15:45 – 16:15       SSM9 Evaluation / Final Discussion

16:15 – 17:00        SSM9 closing comments and overture towards SSM10 in São Paulo and SSM11 in Montréal

 


Advertisements